ARCHIVE.
Identifying effective chemotherapy drugs for cancer patients based on genetic data processing
In the past, oncologists had to test different chemotherapy drugs on patients based on medical guidelines until finding an effective one. This trial-and-error approach often caused severe side effects, weakened the immune system, and in some cases led to patient death. Today, with global scientific advances and genetic profiling, chemotherapy drugs can be tailored to...
The first AI platform for predicting breast cancer risk has been approved by the U.S. Food and Drug Administration (FDA).
Dr. Connie Lehman, founder of Clairity and breast imaging specialist at Massachusetts Brigham Hospital, developed the CLAIRITY BREAST AI platform. Classified as Class II medical software (SaMD), it is the first AI platform approved by the FDA to predict breast cancer risk. Using supervised learning algorithms and mammography images, CLAIRITY BREAST estimates a woman’s risk...